Evidence map›Paper›PMID 30570341›Full record

ArticleLeukemia & lymphoma2019

Retinoic acid and 6-formylindolo(3,2-b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML.

Rodica P Bunaciu, Robert J MacDonald, Holly A Jensen, Feng Gao, Xin Wang, Lynn Johnson, Jeffrey D Varner, Andrew Yen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Roscovitine enhances all-Oncotarget · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Rodica P Bunaciua Department of Biomedical Sciences , Cornell University , Ithaca , NY , USA.
Robert J MacDonalda Department of Biomedical Sciences , Cornell University , Ithaca , NY , USA.
Holly A Jensena Department of Biomedical Sciences , Cornell University , Ithaca , NY , USA.
Feng Gaoa Department of Biomedical Sciences , Cornell University , Ithaca , NY , USA.
Xin Wangc Department of Biomedical Sciences , City University of Hong Kong , Hong Kong , China.
Lynn Johnsond Cornell Statistical Unit , Cornell University , Ithaca , NY , USA.
Jeffrey D Varnerb Robert Frederick Smith School of Chemical and Biomolecular Engineering , Cornell University , Ithaca , NY , USA.
Andrew Yena Department of Biomedical Sciences , Cornell University , Ithaca , NY , USA.
Cornell University · USCity University of Hong Kong · HK

Funding

Project 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI CANTLEY, LEWIS C., FISCHBACH, CLAUDIA · 2016 to 2020
$10.2M
Mechanism of Action of Retinoic Acid Using CD38R01CA152870 · NCI · CORNELL UNIVERSITY · PI HAO, QUAN, LIN, HENING · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA152870NCI NIH HHS U54 CA210184
6 · The paper itself

Abstract

In non-acute promyelotic leukemia (APL)- non myelocytic leukemia (AML), identification of a signaling signature would predict potentially actionable targets to enhance differentiation effects of all-trans-retinoic acid (RA) and make combination differentiation therapy realizable. Components of such a signaling machine/signalsome found to drive RA-induced differentiation discerned in a FAB M2 cell line/model (HL-60) were further characterized and then compared against AML patient expression profiles. FICZ, known to enhance RA-induced differentiation, was used to experimentally augment signaling for analysis. FRET revealed novel signalsome protein associations: CD38 with pS376SLP76 and caveolin-1 with CD38 and AhR. The signaling molecules driving differentiation in HL-60 cluster in non-APL AML

Indexed as

Antineoplastic AgentsApoptosisBiomarkers, TumorCarbazolesCell DifferentiationDrug Resistance, NeoplasmDrug SynergismDrug Therapy, CombinationGene Expression Regulation, NeoplasticHL-60 CellsHumansLeukemia, Myeloid, AcuteLeukemia, Promyelocytic, AcuteSignal TransductionTretinoin6-formylindolo(3,2-b)carbazoleAntineoplastic AgentsBiomarkers, TumorCarbazolesTretinoindifferentiationFICZHL-60neutrophilRetinoic acid

Identifiers

PMID30570341
PMCPMC6586535
OpenAlexW2905782394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.